The heterometallic ruthenium-platinum complexes display multifunctional interactions with nuclear DNA, mitochondrial DNA, RNA, and proteins via different metal centers and are applicable as anticancer agents, photodynamic therapy agents, anti-diabetic agents, and molecular sensors for thiol containing peptides. These multimetallic ruthenium-platinum complexes display synergistic effects between the metal centers, making them more efficient compared to their monometallic precursors. A significant number of reported ruthenium-platinum complexes exhibit enhanced cytotoxicity as well as tumor selectivity compared to cisplatin and their Ru-based monometallic precursors. For example, photoactive Ru(II)Pt(II) complexes were designed to prelocalize a photodynamic therapy agent at the site of action due to the covalent binding of cis-Pt^IICl₂ moiety to DNA. Recent advancement in the development of ruthenium-platinum-based heterometallic complexes provide new directions for more effective drug development. This article presents a comprehensive review of the development of ruthenium and platinum-based mixed-metal complexes including, Ru(III)Pt(II), Ru(II)Pt(IV), photoactive Ru(II)Pt(II) and nonphotoactive Ru(II)Pt(II) complexes, with therapeutic and biomedical applications. Finally, a general outlook on future directions in the field of development of multimetallic ruthenium-platinum complexes for therapeutic use is discussed.

异金属钌铂络合物通过不同的金属中心与核DNA，线粒体DNA，RNA和蛋白质发生多功能相互作用，可用作抗癌剂，光动力治疗剂，抗糖尿病剂和含硫醇肽的分子传感器。这些多金属钌铂络合物在金属中心之间显示出协同效应，使其比单金属前体更有效。与顺铂及其基于钌的单金属前体相比，大量报道的钌-铂配合物表现出增强的细胞毒性以及肿瘤选择性。例如，将光活性Ru（II）Pt（II）络合物设计为将光动力治疗剂预先定位在作用位点，这是由于其的共价结合。DNA的顺式-Pt ^II Cl ₂部分。钌铂基杂金属配合物开发的最新进展为更有效的药物开发提供了新的方向。本文全面概述了钌和铂基混合金属配合物的发展，包括Ru（III）Pt（II），Ru（II）Pt（IV），光敏Ru（II）Pt（II）和非光敏Ru（II）Pt（II）配合物，具有治疗和生物医学应用。最后，讨论了用于治疗用途的多金属钌-铂配合物开发领域的未来方向的总体前景。